Glenmark Pharmaceuticals concalls

Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways

Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).

Call

Guides 15% growth

Glenmark Pharmaceuticals Earnings Call Transcript: Key Takeaways

Glenmark delivered robust 23.1% revenue growth for Q1 FY27, driven by strong recovery in North America and steady India outperformance, despite persistent geopolitical cost pressures.

Call

Guides 15% growth

Glenmark Pharmaceuticals Earnings Call: Key Takeaways

Glenmark aims to become a US$2bn+ revenue company by FY26, shifting its portfolio mix toward >70% branded products by FY30e through global innovation in Oncology, Respiratory, and Dermatology.

Glenmark Pharmaceuticals Earnings Call: Key Takeaways

Glenmark reported 15.8% Q4 revenue growth (INR 37,706 Mn) and 27.5% FY26 growth. Strategy focuses on respiratory, oncology innovations, and U.S. injectable ramp-up following a landmark AbbVie licensing deal.

Glenmark Pharmaceuticals Earnings Call: Key Takeaways

Glenmark delivered strong FY26 growth, hitting gross debt-free status, yet Q4 US margins were squeezed by timing delays and fixed-cost under-absorption.

Glenmark Pharmaceuticals Earnings Call: Key Takeaways

Glenmark Q4 FY26 consolidated revenue grew 15.8% YoY to ₹37,706m with 20.2% EBITDA margin. Growth driven by landmark AbbVie licensing deal and strong momentum in respiratory franchise.